JAMA Clinical Reviews

Narcolepsy is a chronic neurologic disorder that causes severe daytime sleepiness and impaired quality of life. Author Tom Scammell, MD, of Harvard Medical School joins JAMA Deputy Editor Karen Lasser, MD, MPH, to discuss the etiology, clinical presentation, diagnostic evaluation, and treatment of narcolepsy.

Related Content:
Narcolepsy
The Orexin System—A Key Component of Sleep Regulatory Networks and Involvement in Narcolepsy

Respiratory virus vaccine effectiveness and safety for influenza, RSV, and COVID-19 are reviewed, including new evidence, risks, and recommendations. JAMA Deputy Editor Preeti Malani, MD, MSJ, speaks with Rochelle Walensky, MD, MPH, professor of medicine at Harvard Medical School and former CDC Director, about vaccine data, public trust, and the 2026 respiratory virus season.

Related Content:
Respiratory Season Virus Vaccines
RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season
Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season

Cancer vaccines stimulate immune cells to recognize proteins or mutations found on or within cancer cells, facilitating destruction of cancer cells. Several vaccines are approved and others are in development for cancer treatment. Author Nora Disis, MD, JAMA Deputy Editor and Editor in Chief of JAMA Oncology, discusses cancer vaccines and more with JAMA Deputy Editor Mary McDermott, MD.

Related Content:
Vaccines for Cancer

Idiopathic normal pressure hydrocephalus (iNPH) affects approximately 1% to 4% of adults aged 65 years and older and is associated with gait impairment, cognitive decline, and urinary dysfunction. Author Mark G. Luciano, MD, PhD, from Johns Hopkins University, discusses this and more with JAMA Deputy Editor Kristin Walter, MD, MS.

Related Content:
Idiopathic Normal Pressure Hydrocephalus

Rheumatoid arthritis can affect any synovial joint and cause irreversible damage, but early diagnosis and treatment with DMARDs can reduce inflammation and lower the risk of joint destruction. JAMA Associate Editor David Simel, MD, MHS, is joined by review coauthor Josef Smolen, MD, to discuss this topic.

Related Content:
Rheumatoid Arthritis in Adults